ResearcherShanghai Jiao Tong UniversityNo recent work listed
Xiao Zhang
Matched on ORCID iD 0000-0001-5390-364X; OpenAlex author ID A5101841137. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2021: 1 paper · 2022: 1 paper
Papers 2
- HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. Co-author DOI 10.1186/s12935-022-02807-4↗
- CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling pathway. Co-author DOI 10.7150/jca.54482↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xiaofei Zhang · 2 shared papers, 2021–2022 · strength 0.29
- Paper CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling path… DOI 10.7150/jca.54482↗
- Paper HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. DOI 10.1186/s12935-022-02807-4↗
- Tiebo Mao · 2 shared papers, 2021–2022 · strength 0.29
- Paper CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling path… DOI 10.7150/jca.54482↗
- Paper HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. DOI 10.1186/s12935-022-02807-4↗
- Liwei Wang · 2 shared papers, 2021–2022 · strength 0.29
- Paper CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling path… DOI 10.7150/jca.54482↗
- Paper HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. DOI 10.1186/s12935-022-02807-4↗
- Jiujie Cui · 2 shared papers, 2021–2022 · strength 0.29
- Paper CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling path… DOI 10.7150/jca.54482↗
- Paper HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53. DOI 10.1186/s12935-022-02807-4↗
- Weiyu Ge · 1 shared paper, 2022 · strength 0.15
- Shengbai Xue · 1 shared paper, 2022 · strength 0.15
- Shumin Li · 1 shared paper, 2022 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.